^
Association details:
| Biomarker: | IFNG elevation |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictive value of the biomarker of peripheral blood of lung carcinoma patients responding to PD-1 treatment: A real-word study.
Published date:
05/26/2022
Excerpt:
40 non-squamous NSCLC patients, 15 Squamous NSCLC patients and 6 SCLC patients received PD-1 antibody with chemotherapy....The disease control rare(DCR) was 80.4%. In DCR group, higher levels of IFN-γ(P = 0.023,P < 0.05), TNF-α(P = 0.007,P < 0.05)and IL-5 (P = 0.002, P < 0.005) were detected in peripheral blood prior to the treatment comparing to PD group....These results suggest for the first time that serum IFN-γ, TNF-α and IL-5 levels could predict clinical efficacy with anti-PD-1 blockade therapy in lung cancer patients.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2022.40.16_suppl.e20549
